US EditionUPSHER-SMITH TO SHOWCASE RARE DISEASE PORTFOLIO AT 2025 AAN ANNUAL MEETING
- Upsher-Smith will attend the AAN meeting from April 5-9, 2025, in San Diego to showcase its portfolio.
- Upsher-Smith wants to offer resources and support for rare disease patients, caregivers, and practitioners.
- Upsher-Smith's portfolio includes VIGAFYDE, a ready-to-use liquid vigabatrin, and TORPENZ tablets for TSC treatment.
- Jim Maahs, Commercial Head at Upsher-Smith, mentioned broadened offerings, including VIGADRONE and TORPENZ tablets.
- VIGAFYDE is approved for infantile spasms, but vigabatrin products require a Risk Evaluation and Mitigation Strategy.
Insights by Ground AI
Does this summary seem wrong?
19 Articles
19 Articles
All
Left
1
Center
4
Right
Coverage Details
Total News Sources19
Leaning Left1Leaning Right0Center4Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
L 20%
C 80%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
